Chapter 1 Amyloidosis

Kostandinos Sideras, Morie Gertz

Research output: Chapter in Book/Report/Conference proceedingChapter

28 Citations (Scopus)

Abstract

Amyloidosis is a heterogeneous group of diseases in which an otherwise normal protein, with or without proteolytic cleavage, forms insoluble amyloid fibrils. These, in turn, deposit in various organs and cause dysfunction. A wide range of diseases are associated with amyloidosis such as Alzheimer's disease, multiple myeloma, other plasma cell disorders, and chronic inflammation, either as a cause, or result, of amyloid production. This heterogeneity in cause and presentation leads to an incomplete understanding of the pathophysiology of amyloid disease. As such, study of this complicated disease process presents significant challenges. The purpose of this review article is to introduce the biochemistry of amyloidosis including ultrastructure analysis, models of monomer aggregation, the importance of the amyloid microenvironment, and the mechanisms of organ dysfunction, including the role of "toxic intermediates." Pathophysiologic analysis of amyloidosis will focus on diagnostic tools as well as the classification of the various forms of amyloidosis. Finally, treatment of amyloidosis will be reviewed including traditional and established modalities. We will also introduce new and novel treatment options as they relate to the basic pathophysiology of this complex and heterogeneous disorder.

Original languageEnglish (US)
Title of host publicationAdvances in Clinical Chemistry
EditorsGregory Makowski
Pages1-44
Number of pages44
DOIs
StatePublished - Jul 31 2009

Publication series

NameAdvances in Clinical Chemistry
Volume47
ISSN (Print)0065-2423

Fingerprint

Amyloidosis
Amyloid
Biochemistry
Poisons
Plasma Cells
Multiple Myeloma
Deposits
Agglomeration
Monomers
Alzheimer Disease
Plasmas
Inflammation
Proteins

ASJC Scopus subject areas

  • Chemistry(all)
  • Clinical Biochemistry

Cite this

Sideras, K., & Gertz, M. (2009). Chapter 1 Amyloidosis. In G. Makowski (Ed.), Advances in Clinical Chemistry (pp. 1-44). (Advances in Clinical Chemistry; Vol. 47). https://doi.org/10.1016/S0065-2423(09)47001-X

Chapter 1 Amyloidosis. / Sideras, Kostandinos; Gertz, Morie.

Advances in Clinical Chemistry. ed. / Gregory Makowski. 2009. p. 1-44 (Advances in Clinical Chemistry; Vol. 47).

Research output: Chapter in Book/Report/Conference proceedingChapter

Sideras, K & Gertz, M 2009, Chapter 1 Amyloidosis. in G Makowski (ed.), Advances in Clinical Chemistry. Advances in Clinical Chemistry, vol. 47, pp. 1-44. https://doi.org/10.1016/S0065-2423(09)47001-X
Sideras K, Gertz M. Chapter 1 Amyloidosis. In Makowski G, editor, Advances in Clinical Chemistry. 2009. p. 1-44. (Advances in Clinical Chemistry). https://doi.org/10.1016/S0065-2423(09)47001-X
Sideras, Kostandinos ; Gertz, Morie. / Chapter 1 Amyloidosis. Advances in Clinical Chemistry. editor / Gregory Makowski. 2009. pp. 1-44 (Advances in Clinical Chemistry).
@inbook{35a463839a6c4c1584f581df70ab09b9,
title = "Chapter 1 Amyloidosis",
abstract = "Amyloidosis is a heterogeneous group of diseases in which an otherwise normal protein, with or without proteolytic cleavage, forms insoluble amyloid fibrils. These, in turn, deposit in various organs and cause dysfunction. A wide range of diseases are associated with amyloidosis such as Alzheimer's disease, multiple myeloma, other plasma cell disorders, and chronic inflammation, either as a cause, or result, of amyloid production. This heterogeneity in cause and presentation leads to an incomplete understanding of the pathophysiology of amyloid disease. As such, study of this complicated disease process presents significant challenges. The purpose of this review article is to introduce the biochemistry of amyloidosis including ultrastructure analysis, models of monomer aggregation, the importance of the amyloid microenvironment, and the mechanisms of organ dysfunction, including the role of {"}toxic intermediates.{"} Pathophysiologic analysis of amyloidosis will focus on diagnostic tools as well as the classification of the various forms of amyloidosis. Finally, treatment of amyloidosis will be reviewed including traditional and established modalities. We will also introduce new and novel treatment options as they relate to the basic pathophysiology of this complex and heterogeneous disorder.",
author = "Kostandinos Sideras and Morie Gertz",
year = "2009",
month = "7",
day = "31",
doi = "10.1016/S0065-2423(09)47001-X",
language = "English (US)",
isbn = "9780123747969",
series = "Advances in Clinical Chemistry",
pages = "1--44",
editor = "Gregory Makowski",
booktitle = "Advances in Clinical Chemistry",

}

TY - CHAP

T1 - Chapter 1 Amyloidosis

AU - Sideras, Kostandinos

AU - Gertz, Morie

PY - 2009/7/31

Y1 - 2009/7/31

N2 - Amyloidosis is a heterogeneous group of diseases in which an otherwise normal protein, with or without proteolytic cleavage, forms insoluble amyloid fibrils. These, in turn, deposit in various organs and cause dysfunction. A wide range of diseases are associated with amyloidosis such as Alzheimer's disease, multiple myeloma, other plasma cell disorders, and chronic inflammation, either as a cause, or result, of amyloid production. This heterogeneity in cause and presentation leads to an incomplete understanding of the pathophysiology of amyloid disease. As such, study of this complicated disease process presents significant challenges. The purpose of this review article is to introduce the biochemistry of amyloidosis including ultrastructure analysis, models of monomer aggregation, the importance of the amyloid microenvironment, and the mechanisms of organ dysfunction, including the role of "toxic intermediates." Pathophysiologic analysis of amyloidosis will focus on diagnostic tools as well as the classification of the various forms of amyloidosis. Finally, treatment of amyloidosis will be reviewed including traditional and established modalities. We will also introduce new and novel treatment options as they relate to the basic pathophysiology of this complex and heterogeneous disorder.

AB - Amyloidosis is a heterogeneous group of diseases in which an otherwise normal protein, with or without proteolytic cleavage, forms insoluble amyloid fibrils. These, in turn, deposit in various organs and cause dysfunction. A wide range of diseases are associated with amyloidosis such as Alzheimer's disease, multiple myeloma, other plasma cell disorders, and chronic inflammation, either as a cause, or result, of amyloid production. This heterogeneity in cause and presentation leads to an incomplete understanding of the pathophysiology of amyloid disease. As such, study of this complicated disease process presents significant challenges. The purpose of this review article is to introduce the biochemistry of amyloidosis including ultrastructure analysis, models of monomer aggregation, the importance of the amyloid microenvironment, and the mechanisms of organ dysfunction, including the role of "toxic intermediates." Pathophysiologic analysis of amyloidosis will focus on diagnostic tools as well as the classification of the various forms of amyloidosis. Finally, treatment of amyloidosis will be reviewed including traditional and established modalities. We will also introduce new and novel treatment options as they relate to the basic pathophysiology of this complex and heterogeneous disorder.

UR - http://www.scopus.com/inward/record.url?scp=67651244309&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67651244309&partnerID=8YFLogxK

U2 - 10.1016/S0065-2423(09)47001-X

DO - 10.1016/S0065-2423(09)47001-X

M3 - Chapter

C2 - 19634775

AN - SCOPUS:67651244309

SN - 9780123747969

T3 - Advances in Clinical Chemistry

SP - 1

EP - 44

BT - Advances in Clinical Chemistry

A2 - Makowski, Gregory

ER -